All Releases
 |
/C O R R E C T I O N -- Insmed Inc./
May 8, 2008
|
33.1 KB |
| |
RICHMOND, Va., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- The news release, Insmed (Nasdaq: INSM) Announces First Quarter 2008 Financial Results, issued earlier today by Insmed Inc., was incorrectly transmitted by PR Newswire. Complete, corrected release follows:
Insmed Announces First Quarter 2008 Financial Results
Insme...
|
|
Insmed Announces First Quarter 2008 Financial Results
May 8, 2008
|
19.5 KB |
| |
RICHMOND, Va., May 8, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOB) and biopharmaceuticals, today reported results for the first quarter ended March 31, 2008.
Recent Company Highlights
-- Follow-on Biologics Program
-- Received regulatory approval f...
|
|
Insmed Provides Update on Follow-On Biologics and IPLEX(TM) Programs
Apr 29, 2008
|
22.9 KB |
| |
RICHMOND, Va., April 29, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOBs) and biopharmaceuticals, today provided an update of the status of its initial FOB development candidates, INS-19 (a FOB of Neupogen(R)) and INS-20 (a FOB of Neulasta(R)) which represent combined 2007 ...
|
|
Insmed to Host First Quarter 2008 Conference Call
Apr 24, 2008
|
18.5 KB |
| |
RICHMOND, Va., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it will host a conference call on Thursday, May 8th at 8:30 AM ET, to discuss its results for the first quarter 2008. Insmed intends to issue its quarterly financ...
|
|
Insmed to Present at CBI Follow-On Biologics Conference
Apr 22, 2008
|
18.0 KB |
| |
RICHMOND, Va., April 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics (FOBs) and biopharmaceuticals, announced today that Geoffrey Allan, Ph.D., CEO of Insmed, will present at the Center for Business Intelligence (CBI) conference on FOBs, on April 29, 2008 at 2:15 PM Eastern T...
|
|
Insmed Initiates Clinical Study for Follow-on Biologic Version of Neupogen(R)
Apr 16, 2008
|
19.3 KB |
| |
RICHMOND, Va., April 16, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has received approval from the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) to initiate the Company's first clinical study for a...
|
|
Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Apr 10, 2008
|
18.9 KB |
| |
RICHMOND, Va., April 10, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced receipt of a letter and questionnaire from the Chairman and Ranking Member of the U.S. House of Representatives' Subcommittee on Health on the possible development of ...
|
|
Insmed Announces Additional Information in Compliance With NASDAQ Rules
Mar 18, 2008
|
16.4 KB |
| |
RICHMOND, Va., March 18, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Pursuant to NASDAQ Marketplace Rule 4350(b)(1)(B) (the "NASDAQ Rule") any Company whose securities are listed on one of the NASDAQ stock exchanges that receives a going concern audit opinion in one of its filings with the Securities and Exchange Commission is required t...
|
|
Insmed Announces Fourth Quarter and Full-Year 2007 Financial Results
Mar 4, 2008
|
30.0 KB |
| |
RICHMOND, Va., March 4, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq CM: INSM), a developer of follow-on biologics and biopharmaceuticals, today reported results for the quarter and full-year ended December 31, 2007.
Full-Year 2007 and Recent Company Highlights
-- Follow-on Biologics Program
...
|
|
Insmed Announces Listing Transfer from Nasdaq Global Market to Nasdaq Capital Market
Feb 28, 2008
|
18.4 KB |
| |
RICHMOND, Va., Feb 28, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that on February 27, 2008, it received a letter from the Nasdaq Listings Qualifications Panel (the "Panel") stating that the Panel has determined to transfer the listing...
|
|
Insmed to Host Fourth Quarter and Full-Year 2007 Conference Call
Feb 19, 2008
|
18.8 KB |
| |
RICHMOND, Va., Feb 19, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it will host a conference call on Tuesday, March 4th at 8:30 AM ET, to discuss its results for the fourth quarter and full-year 2007. Insmed intends to issue its qu...
|
|
Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Feb 11, 2008
|
21.9 KB |
| |
RICHMOND, Va., Feb 11, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- A report released today, commissioned by Insmed Inc. (Nasdaq: INSM), identifies potential cost savings of approximately $378 billion over the next 20 years from making follow on biologics (FOBs) available in the U.S.
The econometric study by economist Dr. Robert J. Sh...
|
|
Insmed Launches National Awareness Campaign Surrounding Follow-On Biologics
Feb 5, 2008
|
18.9 KB |
| |
RICHMOND, Va., Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has launched a broad education campaign on the importance of establishing a regulatory pathway in the U.S. for large molecule protein-based drugs, known as follo...
|
|
Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
Feb 5, 2008
|
18.2 KB |
| |
RICHMOND, Va., Feb 05, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM) CEO Geoffrey Allan issued the following statement today following the White House FY09 Budget and Food and Drug Administration statements on developing an approval pathway for follow-on biologics:
"Insmed is very pleased to see that the Whit...
|
|
Insmed Provides Update on IPLEX(TM) Expanded Access Program in Italy for the Treatment of Amyotrophic Lateral Sclerosis
Jan 24, 2008
|
19.7 KB |
| |
RICHMOND, Va., Jan 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today provided an update on the IPLEX(TM) Expanded Access Program (EAP) in Italy for the treatment of Amyotrophic Lateral Sclerosis (ALS). Since early 2007, the EAP has grown to include...
|
|
Insmed Completes External Assessment of Myotonic Muscular Dystrophy Market
Jan 22, 2008
|
18.7 KB |
| |
RICHMOND, Va., Jan 22, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that a leading management consulting firm has completed a market assessment of the potential market for therapeutic treatments related to Myotonic Muscular Dystrophy (MM...
|
|
Insmed to Appeal Delisting Notification From Nasdaq
Dec 26, 2007
|
16.6 KB |
| |
RICHMOND, Va., Dec 26, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that it has requested a hearing before a Nasdaq Listing Qualifications Panel to appeal an earlier Staff Determination to delist the Company's common stock from the Nasda...
|
|
Insmed Receives FDA Orphan Drug Designation for IPLEX(TM) in the Treatment of Myotonic Muscular Dystrophy
Dec 18, 2007
|
19.1 KB |
| |
RICHMOND, Va., Dec 18, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation for IPLEX(TM) for the treatment of Myotonic Muscular Dystrophy (MMD). Insmed is currently...
|
|
Insmed Awarded $2.1 Million by Muscular Dystrophy Association
Dec 12, 2007
|
18.9 KB |
| |
RICHMOND, Va., Dec 12, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), today announced that it has been awarded a grant of $2,087,325 from the Muscular Dystrophy Association (MDA). The grant is expected to cover a substantial portion of the external costs associated with Insmed's 24-week Phase 3 enabling trial in ...
|
|
Insmed Appoints Dennis M. Lanfear to Board Of Directors
Dec 6, 2007
|
18.9 KB |
| |
RICHMOND, Va., Dec 06, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Insmed Inc. (Nasdaq: INSM), a developer of follow-on biologics and biopharmaceuticals, today announced the appointment of Mr. Dennis "Denny" Lanfear, 52, to its board of directors. Insmed's board of directors now consists of seven members, five of whom are independent.
...
|
|
|
